These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

946 related items for PubMed ID: 27910803

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
    Berg KD, Brasso K, Thomsen FB, Røder MA, Holten-Rossing H, Toft BG, Iversen P, Vainer B.
    J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
    [Abstract] [Full Text] [Related]

  • 3. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD, Røder MA, Thomsen FB, Vainer B, Gerds TA, Brasso K, Iversen P.
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L, Pan X, Zhang M, Yin X, Gong J, Chen X, Xu M, Zhou Q, Chen N.
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [Abstract] [Full Text] [Related]

  • 9. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.
    Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
    [Abstract] [Full Text] [Related]

  • 10. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR.
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [Abstract] [Full Text] [Related]

  • 11. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
    Sanguedolce F, Cormio A, Brunelli M, D'Amuri A, Carrieri G, Bufo P, Cormio L.
    Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H, Magi-Galluzzi C, Li J, Carver P, Falzarano S, Smith K, Rubin MA, Zhou M.
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [Abstract] [Full Text] [Related]

  • 16. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer.
    Kristensen G, Røder MA, Berg KD, Elversang J, Iglesias-Gato D, Moreira J, Toft BG, Brasso K.
    APMIS; 2018 Oct; 126(10):804-813. PubMed ID: 30191621
    [Abstract] [Full Text] [Related]

  • 17. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.
    Prostate; 2013 Feb 15; 73(3):242-9. PubMed ID: 22821767
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA.
    Cancer Biol Ther; 2009 Jan 15; 8(2):125-30. PubMed ID: 19029822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.